Roberto Díaz Beveridge

513 total citations
13 papers, 128 citations indexed

About

Roberto Díaz Beveridge is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Roberto Díaz Beveridge has authored 13 papers receiving a total of 128 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Roberto Díaz Beveridge's work include Pancreatic and Hepatic Oncology Research (3 papers), Sarcoma Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (2 papers). Roberto Díaz Beveridge is often cited by papers focused on Pancreatic and Hepatic Oncology Research (3 papers), Sarcoma Diagnosis and Treatment (2 papers) and HER2/EGFR in Cancer Research (2 papers). Roberto Díaz Beveridge collaborates with scholars based in Spain and Austria. Roberto Díaz Beveridge's co-authors include Teresa Macarulla, Manuel Hidalgo, Fernando Rivera, Joaquina Martínez-Galán, Ruth Vera, Sofía Perea, Adelaida La Casta, Javier Sastre, Margarita Reboredo and Rafael López‐López and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Radiology and Medical Oncology.

In The Last Decade

Roberto Díaz Beveridge

9 papers receiving 127 citations

Peers

Roberto Díaz Beveridge
Sara Alothman United States
Roberto Díaz Beveridge
Citations per year, relative to Roberto Díaz Beveridge Roberto Díaz Beveridge (= 1×) peers Sara Alothman

Countries citing papers authored by Roberto Díaz Beveridge

Since Specialization
Citations

This map shows the geographic impact of Roberto Díaz Beveridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Díaz Beveridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Díaz Beveridge more than expected).

Fields of papers citing papers by Roberto Díaz Beveridge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Díaz Beveridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Díaz Beveridge. The network helps show where Roberto Díaz Beveridge may publish in the future.

Co-authorship network of co-authors of Roberto Díaz Beveridge

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Díaz Beveridge. A scholar is included among the top collaborators of Roberto Díaz Beveridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Díaz Beveridge. Roberto Díaz Beveridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Gallego, Juan Miguel, et al.. (2025). 122P Risk stratification in soft tissue sarcoma: A single-center experience using Sarculator. ESMO Open. 10. 104435–104435. 1 indexed citations
2.
Martín‐Broto, Javier, Javier Martínez‐Trufero, Roberto Díaz Beveridge, et al.. (2025). ImmunoSarc2 (Cohort 7a): A Spanish Sarcoma Group (GEIS) phase Ib trial of epirubicin and ifosfamide plus nivolumab in first line of advanced undifferentiated pleomorphic sarcoma (UPS).. Journal of Clinical Oncology. 43(16_suppl). 11514–11514.
3.
Martín‐Broto, Javier, Roberto Díaz Beveridge, David S. Moura, et al.. (2023). ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.. Journal of Clinical Oncology. 41(16_suppl). 11502–11502. 8 indexed citations
4.
Martí‐Bonmatí, Luis, et al.. (2022). Pancreatic cancer, radiomics and artificial intelligence. British Journal of Radiology. 95(1137). 20220072–20220072. 22 indexed citations
5.
Macarulla, Teresa, Roberto Pazo-Cid, Carmen Guillén‐Ponce, et al.. (2018). Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. Journal of Clinical Oncology. 37(3). 230–238. 65 indexed citations
7.
Beveridge, Roberto Díaz, et al.. (2014). Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. Medical Oncology. 31(5). 948–948. 8 indexed citations
8.
Beveridge, Roberto Díaz, et al.. (2006). Epidemiological pattern and time trends in testicular germ-cell tumors: a single institution 20-year experience. Clinical & Translational Oncology. 8(8). 588–593. 11 indexed citations
9.
Beveridge, Roberto Díaz, et al.. (2005). Melanoma primario de recto: una neoplasia infrecuente con una forma de presentación atípica. Clinical & Translational Oncology. 7(4). 171–173. 10 indexed citations
10.
Segura, Ángel, et al.. (2004). Manejo farmacológico del dolor crónico oncológico. Una aproximación actual. Clinical & Translational Oncology. 6(5). 272–282. 2 indexed citations
11.
Beveridge, Roberto Díaz, et al.. (2003). Primitive non Hodgkin’s lymphoma of the pancreas in a patient with HIV infection. 5(4). 223–225. 1 indexed citations
12.
Beveridge, Roberto Díaz, et al.. (2003). Leucemias agudas y síndromes mielodisplásicos secundarios al tratamiento oncológico. Anales de Medicina Interna. 20(5). 257–68.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026